SEC Stock Data Quick Answer Nouveau Monde Graphite Inc. reported net income of -C$105.18 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Nouveau Monde Graphite Inc. … Read more
Quick Answer Nouveau Monde Graphite Inc. reported operating profit of -C$59.69 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Nouveau Monde Graphite Inc. … Read more
Quick Answer Nouveau Monde Graphite Inc. reported operating profit of -C$59.69 million for fiscal year 2025, reported under IFRS on Form 20-F. Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Nouveau … Read more
Quick Answer NERVGEN PHARMA CORP. reported r&d expense of C$13.91 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. R&D Expense … Read more
Quick Answer NERVGEN PHARMA CORP. reported operating cash flow of -C$19.50 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. Operating … Read more
Quick Answer NERVGEN PHARMA CORP. reported total equity of C$3.48 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. Total Equity … Read more
Quick Answer NERVGEN PHARMA CORP. reported total liabilities of C$19.73 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. Total Liabilities … Read more
Quick Answer NERVGEN PHARMA CORP. reported total assets of C$23.21 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. Total Assets … Read more
Quick Answer NERVGEN PHARMA CORP. reported diluted eps of C$-0.61 per share for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. Diluted … Read more
Quick Answer NERVGEN PHARMA CORP. reported basic eps of C$-0.61 per share for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. NERVGEN PHARMA CORP. Basic … Read more